Two Fox Chase Clinicians Named to 2022 List of World’s Most Highly Cited Researchers

Hossein Borghaei, DO, MS

Fox Chase Cancer Center physicians Hossein Borghaei, DO, MS, and Elizabeth Plimack, MD, MS, have been named to the 2022 list of Highly Cited Researchers by Clarivate, an information and analytics firm focused on research.

Elizabeth Plimack, MD, MS

Borghaei is chief of the Division of Thoracic Medical Oncology and a professor in the Department of Hematology/Oncology at Fox Chase. In addition to being the center’s Deputy Director, Plimack is also chief of the Division of Genitourinary Medical Oncology and a professor in the Department of Hematology/Oncology.

The annual listing recognizes individuals at universities, research institutes, and commercial organizations “who have demonstrated a disproportionate level of significant and broad influence in their field or fields of research,” according to Clarivate.

“We know clinicians and scientists at Fox Chase do cutting-edge, impactful research every day, something that this award highlights,” said Jonathan Chernoff, MD, PhD, Cancer Center Director.

Since its launch in 2001, the Highly Cited Researchers list has identified clinicians and scientists from around the globe who have demonstrated exceptional influence. Clarivate measures this through the publication by researchers of multiple papers frequently cited by their peers during the last decade. The organization uses data from the Web of Science citation index, as well as analysis performed by bibliometric experts and data scientists at the Institute for Scientific Information at Clarivate.

Borghaei, who specializes in lung cancer research, is a member of the Cancer Signaling and Microenvironment research program at Fox Chase. His lab concentrates on the development of new cancer treatments, with an emphasis on the use of immunotherapy and monoclonal antibodies. He is also active in clinical trials.

Plimack specializes in the treatment of kidney, bladder, and prostate cancer. Her research efforts focus on the development of new therapies for bladder and kidney cancer. She is also a member of the Nuclear Dynamics and Cancer research program at Fox Chase.